**RESULTS**

**Table 1. Patient Demographics and Disease Traits**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Non-OST on TN</th>
<th>Non-OST on NC</th>
<th>mITT on TN</th>
<th>mITT on NC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), years</td>
<td>43 (21-69)</td>
<td>48 (18-86)</td>
<td>43 (21-69)</td>
<td>48 (18-86)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td>194 (68)</td>
<td>298 (32)</td>
<td>217 (69)</td>
<td>306 (69)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td>131 (42)</td>
<td>298 (32)</td>
<td>131 (42)</td>
<td>298 (32)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>24.8 (21.8-29.9)</td>
<td>25.9 (22.3-31.8)</td>
<td>24.8 (21.8-29.9)</td>
<td>25.9 (22.3-31.8)</td>
</tr>
<tr>
<td>Baseline AST, IU/L</td>
<td>114 (7-387)</td>
<td>124 (7-422)</td>
<td>114 (7-387)</td>
<td>124 (7-422)</td>
</tr>
<tr>
<td>Baseline ALT, IU/L</td>
<td>95 (1-254)</td>
<td>113 (1-232)</td>
<td>95 (1-254)</td>
<td>113 (1-232)</td>
</tr>
<tr>
<td>Baseline HCV RNA level, IU/mL</td>
<td>6020 (279 786–4 470 000)</td>
<td>6020 (279 786–4 470 000)</td>
<td>6020 (279 786–4 470 000)</td>
<td>6020 (279 786–4 470 000)</td>
</tr>
</tbody>
</table>

**Figure 1. Efficacy** (ITT and mITT)

- **No virologic failures; all 3 non-responders were due to re-infection**

**Figure 2. Efficacy by Key Subgroups**

- **10/11 patients with active drug use achieved SVR12; 1/11 patients lost to follow-up**
- **100% SVR12 in patients with cirrhosis**

**Safety**

129 patients on OST VS 117 on NC

- **Any adverse event (AE) 23 (19) VS 22 (19)**
- **Grade ≥3 (>3 × ULN) Bili 1 (1) VS 0 (0)**
- **Grade ≥3 (>5 × ULN) AST 1 (1) VS 1 (1)**

**ACKNOWLEDGEMENTS**

The authors would like to express their gratitude to the patients who participated in the study, the investigators, study nurses, and the Leberfeldtungs-GmbH Deutschland, in particular Dr. T. Serfer. Statistical analysis support was provided by Heike Pfeiffer-Vernkahl of e.actus GmbH (Bottich, Germany).

**REFERENCES**


**CONCLUSIONS**

- **Similarly high SVR12 rates in patients with HCV infection on OST and not on OST**
- **No on-treatment virologic failures or relapses; 3 non-responders all due to re-infection**
- **G/P is safe and well-tolerated, with no discontinuations due to AE in patients on OST**

**DISCLOSURES**

J Reimer: Speaker/advisory board/unrestricted educational grant: AbbVie, Bristol-Myers Squibb, Gilead, Janssen-Cilag, MSD.
A Stoehr: Speaker: AbbVie, Gilead, Janssen, and MSD; Advisor: AbbVie and ViV.
U Naumann: Speaker/advisory board for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Mundipharma, MSD, Roche, ViV.
G Teuber: Speaker/Teaching: AbbVie, IMS; Advisory Board: Janssen, Gilead, MSD.
C Sarrazin: Advisory board: AbbVie.
S Mauss: Speaker: AbbVie, Gilead, Falk, and Janssen; Advisor: AbbVie and MSD.
N Quirishi: Speaker/Teaching: AbbVie, Gilead, Janssen, MSD, Mundipharma, Hexal.
S Christophers: Honorary for consulting or speaking at educational events at AbbVie, Gilead, Indivior, Janssen-Cilag, MSD, ViV.
K Lohmann, H Kleinle, and A Pangerl are employees of AbbVie and may hold stock or options.
Financial support was provided by AbbVie. Medical writing support was provided by Zoe Hunter, PhD, of Alkere.

Data were derived from the German Hepatitis C-Registry (Deutsches Hepatitis C-Register), a project of the German Liver Foundation (Deutsche Leberinitiative), managed by Leberfundiungs-GmbH Deutschland in cooperation with the Association of German gastroenterologists in practice (Deutscher gastroenterologischer Verein e.V.).

**DISCLOSURES**

J Reimer: Speaker/advisory board/unrestricted educational grant: AbbVie, Bristol-Myers Squibb, Gilead, Janssen-Cilag, MSD.
A Stoehr: Speaker: AbbVie, Gilead, Janssen, and MSD; Advisor: AbbVie and ViV.
U Naumann: Speaker/advisory board for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Mundipharma, MSD, Roche, ViV.
G Teuber: Speaker/Teaching: AbbVie, IMS; Advisory Board: Janssen, Gilead, MSD.
C Sarrazin: Advisory board: AbbVie.
S Mauss: Speaker: AbbVie, Gilead, Falk, and Janssen; Advisor: AbbVie and MSD.
N Quirishi: Speaker/Teaching: AbbVie, Gilead, Janssen, MSD, Mundipharma, Hexal.
S Christophers: Honorary for consulting or speaking at educational events at AbbVie, Gilead, Indivior, Janssen-Cilag, MSD, ViV.
K Lohmann, H Kleinle, and A Pangerl are employees of AbbVie and may hold stock or options.
Financial support was provided by AbbVie. Medical writing support was provided by Zoe Hunter, PhD, of Alkere.

Data were derived from the German Hepatitis C-Registry (Deutsches Hepatitis C-Register), a project of the German Liver Foundation (Deutsche Leberinitiative), managed by Leberfundiungs-GmbH Deutschland in cooperation with the Association of German gastroenterologists in private practice (Deutscher gastroenterologischer Verein e.V.).

**DISCLOSURES**

J Reimer: Speaker/advisory board/unrestricted educational grant: AbbVie, Bristol-Myers Squibb, Gilead, Janssen-Cilag, MSD.
A Stoehr: Speaker: AbbVie, Gilead, Janssen, and MSD; Advisor: AbbVie and ViV.
U Naumann: Speaker/advisory board for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Mundipharma, MSD, Roche, ViV.
G Teuber: Speaker/Teaching: AbbVie, IMS; Advisory Board: Janssen, Gilead, MSD.
C Sarrazin: Advisory board: AbbVie.
S Mauss: Speaker: AbbVie, Gilead, Falk, and Janssen; Advisor: AbbVie and MSD.
N Quirishi: Speaker/Teaching: AbbVie, Gilead, Janssen, MSD, Mundipharma, Hexal.
S Christophers: Honorary for consulting or speaking at educational events at AbbVie, Gilead, Indivior, Janssen-Cilag, MSD, ViV.
K Lohmann, H Kleinle, and A Pangerl are employees of AbbVie and may hold stock or options.
Financial support was provided by AbbVie. Medical writing support was provided by Zoe Hunter, PhD, of Alkere.